BPC-157 + TB-500

BPC-157 + TB-500 Dosing

BPC-157 runs 250–500 mcg daily, subcutaneous, near the injury site when practical; TB-500 runs 2–4 mg twice weekly, subcutaneous, at least 72 hours apart. Reconstitute each vial on its own — BPC-157 5 mg in 1 mL, TB-500 10 mg in 2 mL — and both land on a clean insulin-syringe draw. Cycle 8–12 weeks active, then taper. Add NAD+ for chronic, post-surgical, or energy-limited recovery.

Two Vials, Two Schedules

BPC-157 and TB-500 are two separate compounds, and they are not dosed the same way. BPC-157 runs daily in micrograms; TB-500 runs twice weekly in milligrams. That difference is the whole reason the stack works, and it is why the recommended form is two individual vials, each reconstituted and dosed on its own schedule. A premixed blend vial is the convenient alternative — one reconstitution at a fixed ratio — but it trades that independent scheduling for a single shared one. Both paths are covered under reconstitution below.

The two peptides cover different bottlenecks in healing. After an injury, the body's emergency response chokes blood flow to the area and traps repair cells (fibroblasts) in place. BPC-157 reopens the blood supply by signaling new capillaries to grow (angiogenic signaling¹). TB-500 supports the repair-cell movement that lets new tissue organize once the blood supply returns (actin-binding repair signal²). Run one without the other and you get the half-healed state most people know: blood flow returns but cells do not organize, or cells mobilize but starve before they can rebuild.

No human trial has tested the combination. BPC-157's evidence is preclinical with one 12-patient clinical study³; TB-4 (the full-length parent of the TB-500 fragment) has roughly 50 preclinical studies and Phase 1 human safety data⁴. The protocol below is practitioner-derived — built on each compound's mechanism and a decade of injury-recovery use, not on a controlled trial of the pair.

For the mechanism deep-dives, see the standalone guides: BPC-157 and TB-500 / TB-4. For the narrative injury-recovery walkthrough, see the Wolverine Stack guide.

How to Reconstitute: Start Here

One question sets up everything else: are you reconstituting two individual vials, or one combined blend vial?

• Individual vials — BPC-157 and TB-500 in separate vials. Reconstitute each on its own and dose each on its own schedule. Recommended, because it lets BPC-157 run daily and TB-500 run twice weekly without compromise.
• Combined blend vial — both peptides premixed in one vial at a fixed ratio. One reconstitution, and every draw delivers both at that ratio. Convenient, but it couples the two schedules into one.

Every case below uses the same formula:

$$V_{\text{draw}}=\frac{D\times V_{\text{water}}}{M}$$

$V_{\text{draw}}$ is the syringe draw (mL), $D$ the target dose, $V_{\text{water}}$ the BAC water added (mL), and $M$ the vial mass of the compound being solved for. Match the units of $D$ and $M$: both mg, or both mcg.

Path 1 — Individual vials (recommended)

Reconstitute each vial separately, then dose on its own schedule.

BPC-157 — 500 mcg daily. The two common vial sizes both land on a 10-unit draw:

$$V_{\text{draw}}=\frac{500\text{ mcg}\times 1\text{ mL}}{5000\text{ mcg}}=0.1\text{ mL}=10\text{ units on a U-100 syringe}$$

• 5 mg vial + 1 mL BAC water → 0.1 mL (10 units) delivers 500 mcg; lasts 10 doses
• 10 mg vial + 2 mL BAC water → 0.1 mL (10 units) delivers 500 mcg; lasts 20 doses
• For a 250 mcg starting dose, halve the draw to 0.05 mL (5 units)

TB-500 — 2.5 mg twice weekly. Both sizes land on a 50-unit draw:

$$V_{\text{draw}}=\frac{2.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.5\text{ mL}=50\text{ units on a U-100 syringe}$$

• 10 mg vial + 2 mL BAC water → 0.5 mL (50 units) delivers 2.5 mg; lasts 4 doses
• 5 mg vial + 1 mL BAC water → 0.5 mL (50 units) delivers 2.5 mg; lasts 2 doses
• For a 2 mg dose, the same reconstitution gives a 0.4 mL (40-unit) draw

On the two days a week the schedules overlap, BPC-157 and TB-500 are pH compatible and can be co-drawn into one syringe. Separate injections work identically. NAD+ is the exception — acidic, degrades peptides on contact, so it always gets its own syringe and site.

Path 2 — Combined blend vial

A blend vial holds both peptides at a fixed mass ratio, so one reconstitution sets both, and every draw delivers them in that ratio. The tradeoff: you pick one schedule for the pair instead of running each on its own.

Standard 1:1 blends — 5/5 and 10/10. Equal mass of each peptide. A "10 mg wolverine stack" is 5 mg BPC-157 + 5 mg TB-500; a "20 mg" is 10 mg + 10 mg.

• 5/5 vial (10 mg total) + 1 mL BAC water → each 0.1 mL (10-unit) draw delivers 0.5 mg BPC-157 and 0.5 mg TB-500
• 10/10 vial (20 mg total) + 2 mL BAC water → same 0.5 mg + 0.5 mg per 0.1 mL draw, with twice the doses per vial

Because the ratio is 1:1, a daily 0.1 mL draw keeps BPC-157 in its usual 500 mcg range but delivers TB-500 every day rather than pulsed twice weekly. That is the blend tradeoff; separate vials (Path 1) avoid it.

Custom (non-1:1) blends — anchor one compound. When the two masses are not equal, pick the compound whose dose you want to fix — the anchor — set its dose, and the other peptide scales by the ratio. This is the same anchor math the KLOW calculator uses.

Example — a 10 mg BPC-157 / 5 mg TB-500 vial (a 2:1 blend), anchored to 500 mcg BPC-157, reconstituted in 2 mL:

$$V_{\text{draw}}=\frac{0.5\text{ mg}\times 2\text{ mL}}{10\text{ mg}}=0.1\text{ mL}=10\text{ units}$$

That same 0.1 mL draw also delivers 250 mcg TB-500 — half the BPC-157 dose, by the 2:1 ratio.

The Calculator above solves either path — individual vials or a blend at any ratio — for any vial size or target dose.

Dosing Protocol

Cycle length: 8–12 weeks for BPC-157, 6–10 weeks for TB-500. TB-500 can taper to once weekly after week 6 if the injury is stable.

Cycle structure

BPC-157 stays daily throughout; TB-500 front-loads, then tapers as the tissue starts holding.

Why BPC-157 is daily and TB-500 is not

The two peptides are dosed differently because they work differently.

BPC-157 delivers a signal. A small daily dose triggers repair cascades — new blood vessel formation, nitric oxide production, repair-cell migration¹ — that keep running after the peptide itself clears. Daily dosing keeps that signaling environment switched on.

TB-500 works by saturation, not by a daily switch. It behaves as a mass-action factor — the repair-cell signal tracks sustained systemic concentration, so it needs a loading phase to build up, and microdosing it does not work: below saturation it never recruits enough repair cells to matter². That is why the convention front-loads it (3–4 mg twice weekly through weeks 1–4) and tapers toward maintenance once the tissue is holding. BPC-157's daily cadence keeps a threshold signal lit; TB-500's twice-weekly loading fills a reservoir the repair-cell mechanism draws down over the following days.

Weekly schedule

Consistency matters more than specific days — keep at least 72 hours between TB-500 doses. Monday and Thursday are the overlap days where the two can share a syringe. If NAD+ is in the protocol, place it on separate injections, 3x weekly, never mixed into the peptide syringe.

Injection routing

Inject near the injury site when it is easy and safe to reach. Neither peptide "stays local" — both enter systemic circulation within minutes — but local injection may give a higher first-pass tissue concentration before that dilution⁵. Safe placement matters more than a perfect site: for hard-to-reach injuries (spine, deep hip), abdomen or thigh works. See Where to Inject Peptides for the full breakdown.

How the Stack Works

Healing stalls when two things fail at once: the blood supply to the injury closes down, and the repair cells that rebuild tissue cannot move into position. The stack assigns one peptide to each problem.

BPC-157: blood supply

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. It restores blood flow to damaged tissue, mainly by signaling blood vessel cells to sprout new capillaries into the area (angiogenic signaling¹). It also restores nitric oxide production, which keeps existing vessels open, and activates the pathway repair cells use to anchor and pull themselves toward the injury (FAK-paxillin signaling⁶). Injured areas often "warm up" in the first week as circulation returns. Without that blood supply, repair materials never reach the work.

TB-500: repair-cell movement

TB-500 is usually the thymosin beta-4 fragment 17–23, the short sequence tied to repair-cell movement. Every cell has internal scaffolding made of actin; TB-500 supports the actin-side signal repair cells use to migrate into damaged tissue (actin-binding repair signal²). Where BPC-157 restores the blood supply, TB-500 helps the right cells reach the right place so tissue can organize rather than scar.

One caution on identity: TB-500 (the fragment) and full-length TB-4 (43 amino acids) are related but not interchangeable, and product labels blur the two routinely⁷. The stronger anti-scarring and tissue-remodeling claims come from full-length TB-4 research, not the isolated fragment. If scar remodeling is the goal, confirm the molecular weight on the certificate of analysis: around 800 Da is the fragment, around 4,900 Da is full-length. See the TB-500 guide for the full distinction.

Why they need each other

In a rat model, combined BPC-157 + TB-4 restored contractile function earlier than either compound alone⁸.

What the Wolverine Stack Is Not For

The stack does one thing: it clears the perfusion-and-migration bottleneck — BPC-157 reopens blood flow, TB-500 moves repair cells along it. It works wherever that coupled bottleneck is what stalled healing: tendon, ligament, muscle, fascia, joint capsule, and scar or connective tissue. Where a different bottleneck governs the tissue, restoring blood flow and cell migration never reaches the thing that is actually stuck.

One honest caveat: BPC-157 and TB-500 show isolated preclinical signals in spinal-cord-injury models, so the precise statement is that the Wolverine Stack is a peripheral soft-tissue tool — not that the peptides are inert everywhere else. For a real-world protocol, bone, cartilage, nerve, and CNS are out of scope by mechanism.

When to Add NAD+

BPC-157 + TB-500 cover blood supply and cell movement — the layers most injuries need first. NAD+ is the first thing to add when those two are working but progress stalls anyway, because repair cells cannot build collagen or remodel tissue without enough cellular energy.

Add NAD+ from the start under any of these: a chronic or 6-month-plus injury, post-surgical recovery, high training load, or recovery that feels systemically draining. 50–250 mg IM, about 3x weekly, in a separate syringe and a separate site — NAD+ is acidic (pH 3–4) and will degrade the peptides if co-injected. It also stings; a slow push and a room-temperature solution help.

NAD+ is not the only possible add, but it is the default first one. The other two layers are conditional:

• GHK-Cu — add when tissue feels mushy rather than elastic under load, a sign of poor collagen quality. Copper-peptide collagen signaling is the gap it fills.
• KPV — add when inflammation keeps cycling back (swelling returns after moderate activity despite four-plus weeks). It pre-empts the inflammation switch (NF-κB⁹).

For all three layers at once, the Injury Recovery Protocol is the cleaner path than bolting compounds onto this stack one at a time.

Tell FoxAI about your injury and it builds the right protocol→

Phenotype Considerations

• Chronic injuries (6+ months). Expect more than two bottlenecks — established scar tissue and adapted blood-supply patterns on top of the vascular and migration layers this stack addresses. Plan for NAD+ from the start and a full 12-week cycle.
• Post-surgical. Defer until the initial clotting window has settled (usually two weeks) unless a clinician directs otherwise. Early angiogenesis can complicate fresh surgical healing.
• On a GLP-1 or in a caloric deficit. Repair runs on energy the deficit is restricting. NAD+ becomes a first-line add rather than a conditional one, and protein intake matters more (see Supporting Factors).
• WADA-tested athletes. TB-500 is prohibited and BPC-157 is WADA S0; the stack is not usable in tested competition. Metabolites of both are detectable.

Supporting Factors

Peptides provide the repair signal. The raw materials come from nutrition and loading.

Movement is not optional. New collagen aligns along the lines of mechanical stress, so without controlled loading it forms as disorganized scar. The peptides and physical therapy are synergistic; neither replaces the other.

When Progress Stalls

Read the stall pattern instead of pushing the dose higher.

• Early improvement that levels off. The vascular and migration bottlenecks have cleared and a different one — energy, collagen quality, or inflammation — is now rate-limiting. Identify which and add the matching layer (NAD+, GHK-Cu, or KPV).
• Tissue warm but energy flagging. Repair has the signal but not the fuel. Add or tighten NAD+; check the protein floor and sleep first.
• Nothing by week 3. Usually a materials or technique problem before it is a dose problem. Verify the certificate of analysis, injection technique, and storage (refrigerated, protected from light) — peptide degradation is the most common cause of non-response.
• Scar remodeling specifically not improving. Confirm vial identity. The anti-scarring effect runs through full-length TB-4, not the TB-500 fragment⁷; a fragment labeled as full-length will not deliver it.

Safety & Considerations

• Active cancer or malignancy within two years. Both peptides promote new blood-vessel formation, which could theoretically support an existing tumor's blood supply. A hard contraindication during active treatment and a caution within two years of remission.
• Pregnancy or breastfeeding. No safety data for either peptide.
• Proliferative retinopathy. New blood-vessel formation may worsen the pathology.
• Recent or planned surgery. Wait until the initial clotting window has settled unless a clinician directs otherwise.
• Therapeutic anticoagulation, active autoimmune disease, or concurrent corticosteroids. Use only with medical supervision — steroids oppose the repair mechanisms these peptides drive, and TB-500 shifts immune-cell behavior in ways that can interact with autoimmune conditions.

The realistic alternative for a stalled soft-tissue injury is not placebo. It is NSAIDs, which suppress the inflammatory phase and can weaken collagen quality, or corticosteroid injections, which suppress the repair cells the tissue needs. Both manage symptoms at the cost of the repair process; the stack targets the repair process directly.

Regulatory & Legal Status

Neither BPC-157 nor TB-500 is FDA-approved for any use, and neither is an approved injury therapy. That status is an access and economics artifact, not a safety verdict — both are largely unpatentable peptides, so no sponsor funds the multi-phase trials approval requires.

FDA compounding status. In late 2023 the FDA placed both peptides on its Category 2 bulk drug substances list, which effectively blocked compounding pharmacies from preparing them. In April 2026 the FDA removed both from Category 2 after the original nominations were withdrawn, and both are slated for formal review by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026 to determine whether they return to the 503A bulks list. This is a shifting access picture, not a therapeutic rejection — verify the current status before sourcing.

WADA (sport) status. Both are prohibited at all times, in and out of competition. BPC-157 is classified under S0 (non-approved substances); TB-500 falls under S2 (peptide hormones and growth factors). Metabolites of both are detectable on testing, so the stack is not usable for any drug-tested athlete.

What Evidence Exists

FAQ

Related Topics

• BPC-157 + TB-500 Calculator — Reconstitution and per-dose math for both vials
• Wolverine Stack Guide — The narrative injury-recovery walkthrough and weekly timeline
• Injury Recovery Peptide Protocol — Five-compound framework adding NAD+, GHK-Cu, and KPV
• BPC-157 Guide — Standalone dosing, oral vs injectable, pharmacokinetics
• TB-500 / TB-4 Guide — Fragment vs full-length, certificate-of-analysis verification
• NAD+ Guide — Cellular energy support for stalled healing
• KLOW Dosage Calculator — Four-peptide blend that includes BPC-157 and TB-4 for skin and tissue repair
• Peptide Calculator — General-purpose reconstitution and dosing calculator
• Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, endothelial sprouting, anti-cytokine modulation: PMC8275860

² TB-500 / TB-4 G-actin sequestration — actin-monomer binding maintains the reserve pool repair cells draw on for migration; mass-action pharmacodynamics favor bolus dosing: PubMed 12581423

³ BPC-157 systematic review — 36 studies (35 preclinical, 1 clinical with 12 patients); VEGF upregulation, eNOS activation, FAK-paxillin cascade. Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." HSS J. 2025. PMC12313605

⁴ TB-4 Phase 1 safety — 84 healthy volunteers tolerated recombinant thymosin beta-4 up to 25 μg/kg daily for 10 days with no serious adverse events. Wang D et al. Ann Transl Med. 2021;9(15):1232. PMC8419156

⁵ TB-4 local-versus-systemic tissue concentration — free systemic TB-4 at a matched total dose produced no functional improvement versus a locally-targeted formulation; systemic dilution dropped tissue concentration below threshold: PMC5396927

⁶ BPC-157 tendon outgrowth — FAK-paxillin signaling promotes repair-cell outgrowth and migration. Chang et al. J Appl Physiol. 2011. PubMed 21030672

⁷ TB-4 / TB-500 mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed products. Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁸ Combined BPC-157 + TB-4 — combined administration restored contractile function earlier than either compound alone. Rahman OF et al. "Therapeutic Peptides in Orthopaedics." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158

⁹ KPV NF-κB inhibition — blocks nuclear translocation of NF-κB, suppresses inflammatory transcription while preserving normal immune signaling: PubMed 18061177

¹⁰ Collagen supplementation — systematic review of collagen peptide effects on synthesis and recovery; pre-exercise timing. Kirmani BH et al. Amino Acids. 2021. PMC8521576

¹¹ BPC-157 and tumor risk — narrative review of regeneration versus cancer risk; preclinical data suggests anti-tumorigenic properties in some contexts. McGuire FP et al. "Regeneration or Risk?" Curr Rev Musculoskelet Med. 2025;18(12):611–619. PMC12446177

This content is for educational purposes only. BPC-157 and TB-500 are not FDA-approved injury therapies. No human RCT exists for the combination — every protocol here is practitioner-derived, based on each compound's mechanism and clinical observation. Consult a physician before beginning any peptide protocol, particularly with active cancer, autoimmune conditions, or medications affecting immune function or coagulation.